R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life
- PMID: 34112729
- DOI: 10.1183/13993003.00917-2021
R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life
Abstract
Rationale: Patients with idiopathic pulmonary fibrosis (IPF) experience impaired health-related quality of life (HRQoL). Several tools have been developed to objectively assess HRQoL in this patient population, but none are in use in routine clinical practice.
Objectives: To develop a rapid, specific tool that can be used for patients with IPF during routine clinic visits.
Methods: A novel and simple five-item numerical rating scale was developed and compared with two other previously validated tools. 100 consecutive patients with IPF managed at a centre for interstitial lung disease were recruited to complete the Raghu scale for pulmonary fibrosis (R-Scale-PF), King's Brief Interstitial Lung Disease questionnaire (K-BILD), and the EuroQol Five-Dimensional Five-Level questionnaire (EQ-5D-5L) in addition to pulmonary function and 6-min walk tests.
Measurements and main results: All 100 patients successfully completed the three HRQoL tools with 53 completing them again at follow-up visits. Internal consistency was high (Cronbach's α 0.825) with minimal floor/ceiling effect. Concurrent validity of the R-Scale-PF was moderate to high compared with the K-BILD (r=-0.713) and the EQ-5D-5L (r=-0.665). Concurrent validity was moderate with physiologic measures (forced vital capacity, r=-0.307, 6-min walking distance, r=-0.383). The R-Scale-PF demonstrated good known-groups validity when comparing scores across stages of disease severity.
Conclusions: The R-Scale-PF correlates well with the K-BILD and EQ-5D-5L. It is hoped that this novel simple numerical rating scale tool, subject to validation in patients from other centres, will provide an opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.
Trial registration: ClinicalTrials.gov NCT04148157.
Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: C. Scallan has nothing to disclose. Conflict of interest: L. Strand has nothing to disclose. Conflict of interest: J. Hayes has nothing to disclose. Conflict of interest: S. Kadura has nothing to disclose. Conflict of interest: B. Collins reports personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work. Conflict of interest: L. Ho has nothing to disclose. Conflict of interest: C. Spada has nothing to disclose. Conflict of interest: W. Canestaro has nothing to disclose. Conflict of interest: M. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation and Canadian Institute for Health Research, other (site PI in industry-sponsored clinical trials) from Roche, grants, personal fees for advisory board work and other (site PI in industry-sponsored clinical trials) from Boehringer Ingelheim, grants and personal fees for advisory board work from Roche, Liminal and Pieris, other (chief editor allowance) from European Respiratory Journal, personal fees for advisory board work from Third Pole, MitoImmune, Abbvie, DevPro Biopharma, Horizon, Algernon and CSL Behring, outside the submitted work. Conflict of interest: G. Raghu has nothing to disclose.
Comment in
-
PROMising developments in IPF patient-reported outcome measures.Eur Respir J. 2022 Jan 13;59(1):2102312. doi: 10.1183/13993003.02312-2021. Print 2022 Jan. Eur Respir J. 2022. PMID: 35027375 No abstract available.
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical